Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octanorm maintenance therapy in dermatomyositis
2017-002710-31Phase 3Terminated
- Sponsor
- Octapharma
- Start
- May 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dermatomyositis (DM) comparing Octanorm with Placebo (2 arms). Primary endpoint: Proportion of patients with clinically important deterioration. Started May 2018; status: terminated.
02
Drugs
Nanogam
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on 2017-002710-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002710-31.